Amicus Therapeutics upgraded by Guggenheim with a new price target
$FOLD
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim upgraded Amicus Therapeutics from Neutral to Buy and set a new price target of $13.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2024 | $18.00 | Buy | Jefferies |
| 5/30/2024 | $18.00 | Overweight | Wells Fargo |
| 5/14/2024 | $13.00 | Neutral → Buy | Guggenheim |
| 12/19/2023 | $15.00 → $20.00 | Equal-Weight → Overweight | Morgan Stanley |
| 9/9/2022 | $14.00 | Equal-Weight | Morgan Stanley |
| 4/13/2022 | $11.00 | Neutral | Goldman |
| 2/24/2022 | $16.00 → $14.00 | Outperform | SVB Leerink |
| 1/14/2022 | $12.00 → $16.00 | Market Perform → Outperform | SVB Leerink |
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2024. "The third quarter of the year was marke
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. Guggenheim Healthcare Innovation Conference in Boston, MA, on Tuesday, November 12, 2024, at 2:30 p.m. ETJefferies London Healthcare Conference in London, U.K. on Tuesday, November 19, 2024, at 8:00 a.m. GMT A live audio webcast of each presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. Additionally, management will attend the J.P. Morgan Equity Opportunities Forum on Wednes
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.ami
Jefferies initiated coverage of Amicus Therapeutics with a rating of Buy and set a new price target of $18.00
Wells Fargo initiated coverage of Amicus Therapeutics with a rating of Overweight and set a new price target of $18.00
Guggenheim upgraded Amicus Therapeutics from Neutral to Buy and set a new price target of $13.00
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
SC 13G/A - AMICUS THERAPEUTICS, INC. (0001178879) (Subject)
Q3 2024 Total Revenue of $141.5M, a 37% Increase Year-over-Year Galafold® Q3 Revenue of $120.4M, up 20% Year-over-Year Pombiliti® + Opfolda® Q3 Revenue of $21.1M, up 33% from Q2 2024 Raising 2024 Total Revenue Growth Guidance to 30%-32% at CER Reducing non-GAAP Operating Expense Guidance to $340M to $350M Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced financial results for the third quarter ended September 30, 2024. "The third quarter of the year was marke
PRINCETON, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2024. Participants and investors interested in accessing the call by phone will need to register using the online registration form. After registering, all phone participants will receive a dial-in number along with a personal PIN to access the event. A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.ami
Q2 2024 Total Revenue of $126.7M, a 34% Increase Year-over-Year Galafold® Q2 Revenue of $110.8M, up 17% Year-over-Year Pombiliti® + Opfolda® Q2 Revenue of $15.9M, up 44% from Q1 2024 Raising 2024 Total Revenue Growth Guidance to 26%-31% at CER and 2024 Galafold Growth Guidance to 14%-18% at CER Narrowing non-GAAP Operating Expense Guidance to $345M to $360M Non-GAAP Profitability Achieved in Q2 and H1 2024 with Acceleration Expected in H2 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for
10-Q - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
8-K - AMICUS THERAPEUTICS, INC. (0001178879) (Filer)
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that Simon Harford has been appointed Chief Financial Officer, effective immediately. Simon brings extensive financial leadership experience, having served in significant finance roles in two global pharmaceutical companies as well as most recently as a public company CFO in the biotechnology industry. Daphne Quimi has decided to retire and will remain an Amicus employee through the end of the year to ensure a smooth transition. "Th
PHILADELPHIA, June 14, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD), today announced the election and appointment of Eiry W. Roberts, M.D. to its Board of Directors. Dr. Roberts is an esteemed drug developer who brings approximately 30 years of pharmaceutical industry experience to the Company's Board of Directors, having served in various leadership positions throughout her career and bringing extensive experience advancing therapies across all phases of drug development. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc., stated, "On behalf of our Board of Directors, I am pleased to announce the appointment of Dr. Eiry Roberts to the Amicus
Most Recently Served as Global Head of Rare Diseases at Sanofi Genzyme Brings Deep Expertise in Corporate Strategy, Business Development and Commercialization PHILADELPHIA, May 06, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) today announced the appointment of Sébastien Martel as Senior Vice President of Strategy and Business Development. Mr. Martel will lead the Company's corporate strategy and business and corporate development endeavors. He will be a member of the Amicus senior leadership team. Mr. Martel brings 25 years of diversified pharmaceutical and biotechnology expertise to Amicus, with extensive experience in rare disease, most recently as Senior Vice President
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
4 - AMICUS THERAPEUTICS, INC. (0001178879) (Issuer)
Wells Fargo initiates coverage on Amicus Therapeutics (NASDAQ:FOLD) with a Overweight rating and announces Price Target of $18.
6 analysts have expressed a variety of opinions on Amicus Therapeutics (NASDAQ:FOLD) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 1 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.5, a high estimate of $22.00, and a low estimate of $13.00. A decline
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Jefferies analyst Kaumil Gajrawala upgraded The Boston Beer Company, Inc. (NYSE:SAM) from Hold to Buy and increased the price target from $335 to $360. Boston Beer shares declined 2.5% to close at $283.82 on Monday. See how other analysts view this stock. JP Morgan analyst Rahul Krotthapalli upgraded the rating on Planet Fitness, Inc. (NYSE:PLNT) from Neutral to Overweight, while boosting the price target from $68 to $78. Planet Fitness shares gained 0.9% to settle at $65.56 on Monday. See how othe